RELAPSE.

Nearly 80% of patients with schizophrenia experience at least 1 relapse within 5 years of diagnosis.[1]

RELAPSE.

Patients with schizophrenia miss nearly one third of their oral antipsychotic doses every year.[2]

RETHINK.

Rx

Is it time we took another look at treatment for schizophrenia?

While no medication can guarantee a relapse will not occur, using long-acting therapies earlier can help you recognize the opportunity for missed doses and intervene when it matters most.

Janssen® is dedicated to finding innovative ways of helping patients with schizophrenia get the medication they need.

References: 1. Robinson D, Woerner MG, Alvir JMJ, et al. Predictors of relapse following response from a first episode of schizophrenia or Schizoaffective Disorder. *Arch Gen Psychiatry*. 1999;56:241-247. **2.** Mahmoud RA, Engelhart LM, Janagap CC, Oster G, Ollendorf D. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: Symptoms, quality of life and resource use under customary clinical care. *Clin Drug Invest*. 2004;24:275-286.

Janssen®
Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Complex puzzles. Comprehensive solutions.

At Western Psychiatric Institute and Clinic of UPMC, we take on complex disorders that some other centers won't even attempt to treat.

But whether a patient has a difficult-to-treat disorder or one more easily treated, teams of specialists in psychiatry, psychopharmacology, clinical psychology, and medicine craft complete, individualized treatment plans that draw upon the latest clinical research, much of it conducted by our own investigators. Whether we're interpreting our clinical trial data or a patient's lab results, our work to advance the understanding and treatment of bipolar disorder, eating disorders, autism, and geriatric behavioral health issues is world-class. In fact, we have one of the world's most comprehensive programs for mood disorders, with research-based treatments for patients at every level of need, at every stage of life.

With more than 400 inpatient psychiatric beds and 75 ambulatory programs, we care for people when they're feeling their worst and support them when they're at their best, back with their families in their home towns. Each year, Western Psychiatric helps some 30,000 people of all ages — at all stages of recovery, from all over the world — live healthier and more productive lives.

UPMC

upmc.com | 1-800-533-UPMC

Affiliated with the **University of Pittsburgh School of Medicine**,
UPMC is ranked among the nation's best hospitals by *U.S.News & World Report*.

SEE ME FOR WHO I CAN BE

GREG, 35*
Diner Worker
Diagnosis: Schizophrenia

*Not an actual patient.

Do you see your patients' full potential?

GEODON is indicated for the treatment of schizophrenia.

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared to placebo. GEODON is not approved for the treatment of patients with dementia-related psychosis.

GEODON is contraindicated in patients with a known history of QT prolongation, recent acute myocardial infarction, or uncompensated heart failure, and should not be used with certain other QT-prolonging drugs. GEODON has a greater capacity to prolong the QT_c interval than several antipsychotics. In some drugs, QT prolongation has been associated with torsade de pointes, a potentially fatal arrhythmia. In many cases this would lead to the conclusion that other drugs should be tried first. Hypokalemia may increase the risk of QT prolongation and arrhythmia.

As with all antipsychotic medications, a rare and potentially fatal condition known as neuroleptic malignant syndrome (NMS) has been reported with GEODON. NMS can cause hyperpyrexia, muscle rigidity, diaphoresis, tachycardia, irregular pulse or blood pressure, cardiac dysrhythmia, and altered mental status. If signs and symptoms appear, immediate discontinuation, treatment, and monitoring are recommended.

Prescribing should be consistent with the need to minimize tardive dyskinesia (TD), a potentially irreversible dose- and duration-dependent syndrome. If signs and symptoms appear, discontinuation should be considered since TD may remit partially or completely.

Hyperglycemia-related adverse events, sometimes serious, have been reported in patients treated with atypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with GEODON, and it is not known if GEODON is associated with these events. Patients treated with an atypical antipsychotic should be monitored for symptoms of hyperglycemia.

Precautions include the risk of rash, orthostatic hypotension, and seizures.

In short-term schizophrenia trials, the most commonly observed adverse events associated with GEODON at an incidence of ≥5% and at least twice the rate of placebo were somnolence and respiratory tract infection.

Please see brief summary of prescribing information on adjacent page.

For more information, please visit www.pfizerpro.com/GEODON

GEODON®
(ziprasidone HCl) **Capsules**

BRIEF SUMMARY. See package insert for full prescribing information.

Increased Mortality in Elderly Patients with Dementia-Related Psychosis—Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Geodon (ziprasidone) is not approved for the treatment of patients with Dementia-Related Psychosis (see WARNINGS).

INDICATIONS—GEODON Capsules is indicated for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar disorder with or without psychotic features. GEODON® (ziprasidone mesylate) for Injection is indicated for acute agitation in schizophrenic patients.

CONTRAINDICATIONS — *QT Prolongation:* Because of GEODON's dose-related prolongation of the QT interval and the known association of fatal arrhythmias with QT prolongation by some other drugs, GEODON is contraindicated in patients with a known history of QT prolongation (including congenital long QT syndrome), with recent acute myocardial infarction, or with uncompensated heart failure (see **WARNINGS**). Pharmacokinetic/pharmacodynamic studies between GEODON and other drugs that prolong the QT interval have not been performed. An additive effect of GEODON and other drugs that prolong the QT interval cannot be excluded. Therefore, GEODON should not be given with dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol, or tacrolimus. GEODON is also contraindicated with drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects and have this effect described in the full prescribing information as a contraindication or a boxed or bolded warning (see **WARNINGS**). GEODON is contraindicated in individuals with a known hypersensitivity to the product. **WARNINGS — *Increased Mortality in Elderly Patients with Dementia-Related Psychosis:*** **Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. GEODON (ziprasidone) is not approved for the treatment of patients with dementia-related psychosis (see BOXED WARNING). *QT Prolongation and Risk of Sudden Death:*** **GEODON use should be avoided in combination with other drugs that are known to prolong the QT_c interval. Additionally, clinicians should be alert to the identification of other drugs that have been consistently observed to prolong the QT_c interval. Such drugs should not be prescribed with GEODON. A study directly comparing the QT/QT_c-prolonging effect of GEODON with several other drugs effective in the treatment of schizophrenia was conducted in patient volunteers. The mean increase in QT_c from baseline for GEODON ranged from approximately 9 to 14 msec greater than for four of the comparator drugs (risperidone, olanzapine, quetiapine, and haloperidol), but was approximately 14 msec less than the prolongation observed for thioridazine. In this study, the effect of GEODON on QT_c length was not augmented by the presence of a metabolic inhibitor (ketoconazole 200 mg bid). In placebo-controlled trials, GEODON increased the QT_c interval compared to placebo by approximately 10 msec at the highest recommended daily dose of 160 mg. In clinical trials the electrocardiograms of 2/2988 (0.06%) GEODON patients and 1/440 (0.23%) placebo patients revealed QT_c intervals exceeding the potentially clinically relevant threshold of 500 msec. In the GEODON patients, neither case suggested a role of GEODON. Some drugs that prolong the QT/QT_c interval have been associated with the occurrence of torsade de pointes and with sudden unexplained death. The relationship of QT prolongation to torsade de pointes is clearest for larger increases (20 msec and greater) but it is possible that smaller QT/QT_c prolongations may also increase risk, or increase it in susceptible individuals, such as those with hypokalemia, hypomagnesemia, or genetic predisposition. Although torsade de pointes has not been observed in association with the use of GEODON at recommended doses in premarketing studies, experience is too limited to rule out an increased risk. A study evaluating the QT/QT_c prolonging effect of intramuscular GEODON, with intramuscular haloperidol as a control, was conducted in patient volunteers. In the trial, ECGs were obtained at the time of maximum plasma concentration following two injections of GEODON (20 mg then 30 mg) or haloperidol (7.5 mg then 10 mg) given four hours apart. Note that a 30 mg dose of intramuscular GEODON is 50% higher than the recommended therapeutic dose. The mean change in QT_c from baseline was calculated for each drug using a sample-based correction that removes the effect of heart rate on the QT interval. The mean increase in QT_c from baseline for GEODON was 4.6 msec following the first injection and 12.8 msec following the second injection. The mean increase in QT_c from baseline for haloperidol was 6.0 msec following the first injection and 14.7 msec following the second injection. In this study, no patient had a QT_c interval exceeding 500 msec. As with other antipsychotic drugs and placebo, sudden unexplained deaths have been reported in patients taking GEODON at recommended doses. The premarketing experience for GEODON did not reveal an excess of mortality for GEODON compared to other antipsychotic drugs or placebo, but the extent of exposure was limited, especially for the drugs used as active controls and placebo. Nevertheless, GEODON's larger prolongation of QT_c length compared to several other antipsychotic drugs raises the possibility that the risk of sudden death may be greater for GEODON than for other available drugs for treating schizophrenia. This possibility needs to be considered in deciding among alternative drug products. Certain circumstances may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QT_c interval, including (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QT_c interval; and (4) presence of congenital prolongation of the QT interval. GEODON should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias (see CONTRAINDICATIONS, and see *Drug Interactions* under PRECAUTIONS). It is recommended that patients being considered for GEODON treatment who are at risk for significant electrolyte disturbances, hypokalemia in particular, have baseline serum potassium and magnesium measurements. Hypokalemia (and/or hypomagnesemia) may increase the risk of QT prolongation and arrhythmia. Hypokalemia may result from diuretic therapy, diarrhea, and other causes. Patients with low serum potassium and/or magnesium should be repleted with those electrolytes before proceeding with treatment. It is essential to periodically monitor serum electrolytes in patients for whom diuretic therapy is introduced during GEODON treatment. Persistently prolonged QT_c intervals may also increase the risk of further prolongation and arrhythmia, but it is not clear that routine screening ECG measures are effective in detecting such patients. Rather, GEODON should be avoided in patients with histories of significant cardiovascular illness, eg, QT prolongation, recent acute myocardial infarction, uncompensated heart failure, or cardiac arrhythmia. GEODON should be discontinued in patients who are found to have persistent QT_c measurements >500 msec. *Neuroleptic Malignant Syndrome (NMS):*** A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs. The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported. ***Tardive Dyskinesia (TD):*** A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients undergoing treatment with antipsychotic drugs. Although the prevalence of TD appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop TD. If signs and symptoms of TD appear in a patient on GEODON, drug discontinuation should be considered. ***Hyperglycemia and Diabetes Mellitus:*** Hyperglycemia-related adverse events, sometimes serious, have been reported in patients treated with atypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with GEODON, and it is not known if GEODON is associated with these events. Patients treated with an atypical antipsychotic should be monitored for symptoms of hyperglycemia. **PRECAUTIONS — *General:*** Rash: In premarketing trials, about 5% of GEODON patients developed rash and/or urticaria, with discontinuation of treatment in about one-sixth of these cases. The occurrence of rash was dose related, although the finding might also be explained by longer exposure in higher-dose patients. Several patients with rash had signs and symptoms of associated systemic illness, e.g., elevated WBCs. Most patients improved promptly upon treatment with antihistamines or steroids and/or upon discontinuation of GEODON, and all patients were reported to recover completely. Upon appearance of rash for which an alternative etiology cannot be identified, GEODON should be discontinued. Orthostatic Hypotension: GEODON may induce orthostatic hypotension associated with dizziness, tachycardia, and, in some patients, syncope, especially during the initial dose-titration period, probably reflecting its α_1-adrenergic antagonist properties. Syncope was reported in 0.6% of GEODON patients. GEODON should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). Seizures: In clinical trials, seizures occurred in 0.4% of GEODON patients. There were confounding factors that may have contributed to seizures in many of these cases. As with other antipsychotic drugs, GEODON should be used cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold, e.g., Alzheimer's dementia. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older. Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia, and GEODON and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. **(See also Boxed WARNING, WARNINGS: Increased Mortality in Elderly Patients with Dementia-Related Psychosis).** Hyperprolactinemia: As with other drugs that antagonize dopamine D_2 receptors, GEODON elevates prolactin levels in humans. Tissue culture experiments indicate that approximately one third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time. Potential for Cognitive and Motor Impairment: Somnolence was a commonly reported adverse event in GEODON patients. In the 4- and 6-week placebo-controlled trials, somnolence was reported in 14% of GEODON patients vs 7% of placebo patients. Somnolence led to discontinuation in 0.3% of patients in short-term clinical trials. Since GEODON has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about performing activities requiring mental alertness, such as operating a motor vehicle (including automobiles) or operating hazardous machinery until they are reasonably certain that GEODON therapy does not affect them adversely. Priapism: One case of priapism was reported in the premarketing database. Body Temperature Regulation: Although not reported with GEODON in premarketing trials, disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Suicide: The possibility of a suicide attempt is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy. GEODON prescriptions should be written for the smallest quantity of capsules consistent with good patient management to reduce overdose risk. Use in Patients with Concomitant Illness: Clinical experience with GEODON in patients with certain concomitant systemic illnesses is limited. GEODON has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical studies. Because of the risk of QT_c prolongation and orthostatic hypotension with GEODON, caution should be observed in cardiac patients (see ***QT Prolongation and Risk of Sudden Death*** in **WARNINGS** and Orthostatic Hypotension in **PRECAUTIONS**). ***Information for Patients:*** To ensure safe and effective use of GEODON, the information and instructions in the *Patient Information Section* should be discussed with patients. ***Laboratory Tests:*** Patients being considered for GEODON treatment who are at risk of significant electrolyte disturbances should have baseline serum potassium and magnesium measurements. Low serum potassium and magnesium should be repleted before treatment. Patients who are started on diuretics during GEODON therapy need periodic monitoring of serum potassium and magnesium. Discontinue GEODON in patients who are found to have persistent QT_c measurements >500 msec (see **WARNINGS**). ***Drug Interactions:*** (1) GEODON should not be used with any drug that prolongs the QT interval. (2) Given the primary CNS effects of GEODON, caution should be used when it is taken in combination with other centrally acting drugs. (3) Because of its potential for inducing hypotension, GEODON may enhance the effects of certain antihypertensive agents. (4) GEODON may antagonize the effects of levodopa and dopamine agonists. Effect of Other Drugs on GEODON: *Carbamazepine*, 200 mg bid for 21 days, resulted in a decrease of approximately 35% in the AUC of GEODON. *Ketoconazole*, a potent inhibitor of CYP3A4, 400 mg qd for 5 days, increased the AUC and C_{max} of GEODON by about 35%-40%. *Cimetidine*, 800 mg qd for 2 days, did not affect GEODON pharmacokinetics. Coadministration of 30 mL of *Maalox* did not affect GEODON pharmacokinetics. Population pharmacokinetic analysis of schizophrenic patients in controlled clinical trials has not revealed any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam. Effect of GEODON on Other Drugs: In vitro studies revealed little potential for GEODON to interfere with the metabolism of drugs cleared primarily by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, and little potential for drug interactions with GEODON due to displacement. GEODON 40 mg bid administered concomitantly with *lithium* 450 mg bid for 7 days did not affect the steady-state level or renal clearance of lithium. GEODON 20 mg bid did not affect the pharmacokinetics of concomitantly administered *oral contraceptives*, ethinyl estradiol (0.03 mg) and levonorgestrel (0.15 mg). Consistent with in vitro results, a study in normal healthy volunteers showed that GEODON did not alter the metabolism of *dextromethorphan*, a CYP2D6 model substrate, to its major metabolite, dextrorphan. There was no statistically significant change in the urinary dextromethorphan/dextrorphan ratio. ***Carcinogenesis, Mutagenesis, Impairment of Fertility:*** Lifetime carcinogenicity studies were conducted with GEODON in Long Evans rats and CD-1 mice. In male mice, there was no increase in incidence of tumors relative to controls. In female mice there were dose-related increases in the incidences of pituitary gland adenoma and carcinoma, and mammary gland adenocarcinoma at all doses tested. Increases in serum prolactin were observed in a 1-month dietary study in female, but not male, mice. GEODON had no effect on serum prolactin in rats in a 5-week dietary study at the doses that were used in the carcinogenicity study. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown (see Hyperprolactinemia). Mutagenesis: There was a reproducible mutagenic response in the Ames assay in one strain of *S. typhimurium* in the absence of metabolic activation. Positive results were obtained in both the in vitro mammalian cell gene mutation assay and the in vitro chromosomal aberration assay in human lymphocytes. Impairment of Fertility: GEODON increased time to copulation in Sprague-Dawley rats in two fertility and early embryonic development studies at doses of 10 to 160 mg/kg/day (0.5 to 8 times the MRHD of 200 mg/day on a mg/m^2 basis). Fertility rate was reduced at 160 mg/kg/day (8 times the MRHD on a mg/m^2 basis). There was no effect on fertility at 40 mg/kg/day (2 times the MRHD on a mg/m^2 basis). The fertility of female rats was reduced. ***Pregnancy—Pregnancy Category C:*** There are no adequate and well-controlled studies in pregnant women. GEODON should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. ***Labor and Delivery:*** The effect of GEODON on labor and delivery in humans is unknown. ***Nursing Mothers:*** It is not known whether, and if so in what amount, GEODON or its metabolites are excreted in human milk. It is recommended that women receiving GEODON should not breast feed. ***Pediatric Use:*** The safety and effectiveness of GEODON in pediatric patients have not been established. ***Geriatric Use:*** Of the approximately 4500 patients treated with GEODON in clinical studies, 2.4% (109) were 65 years of age or over. In general, there was no indication of any different tolerability for GEODON or of reduced clearance of GEODON in the elderly compared to younger adults. Nevertheless, the presence of multiple factors that might increase the pharmacodynamic response to GEODON, or cause poorer tolerance or orthostasis, should lead to consideration of a lower starting dose, slower titration, and careful monitoring during the initial dosing period for some elderly patients. **ADVERSE REACTIONS — *Adverse Findings Observed in Short-term, Placebo-Controlled Trials:*** The following findings are based on the short-term placebo-controlled premarketing trials for schizophrenia (a pool of two 6-week, and two 4-week fixed-dose trials) and bipolar mania (a pool of two 3-week flexible-dose trials) in which GEODON was administered in doses ranging from 10 to 200 mg/day. ***Adverse Events Associated with Discontinuation:*** Schizophrenia: Approximately 4.1% (29/702) of GEODON-treated patients in short-term, placebo-controlled studies discontinued treatment due to an adverse event, compared with about 2.2% (6/273) on placebo. The most common event associated with dropout was rash, including 7 dropouts for rash among GEODON patients (1%) compared to no placebo patients (see **PRECAUTIONS**). Bipolar Mania: Approximately 6.5% (18/279) of GEODON-treated patients in short-term, placebo-controlled studies discontinued treatment due to an adverse event, compared with about 3.7% (5/136) on placebo. The most common events associated with dropout in the GEODON-treated patients were akathisia, anxiety, depression, dizziness, dystonia, rash, and vomiting, with 2 dropouts for each of these events among GEODON patients (1%) compared to one placebo patient each for dystonia and rash (1%) and no placebo patients for the remaining adverse events. ***Adverse Events at an Incidence ≥5% and at Least Twice the Rate of Placebo:*** The most commonly observed adverse events associated with GEODON in schizophrenia trials were somnolence (14%) and respiratory tract infection (8%). The most commonly observed adverse events associated with the use of GEODON in bipolar mania trials were somnolence (31%), extrapyramidal symptoms (31%), dizziness (16%), akathisia (10%), abnormal vision (6%), asthenia (6%), and vomiting (5%). The following list enumerates the treatment-emergent adverse events that occurred during acute therapy, including only those events that occurred in 2% of GEODON patients and at a greater incidence than in placebo. Schizophrenia: Body as a Whole—asthenia, accidental injury, chest pain. Cardiovascular—tachycardia. Digestive—nausea, constipation, dyspepsia, diarrhea, dry mouth, anorexia. Nervous—extrapyramidal symptoms, somnolence, akathisia, dizziness. Respiratory—respiratory tract infection, rhinitis, cough increased. Skin and Appendages—rash, fungal dermatitis. Special Senses—abnormal vision. Bipolar Mania: Body as a Whole—headache, asthenia, accidental injury. Cardiovascular—hypertension. Digestive—nausea, diarrhea, dry mouth, vomiting, increased salivation, tongue edema, dysphagia. Musculoskeletal—myalgia. Nervous—somnolence, extrapyramidal symptoms, dizziness, akathisia, anxiety, hypesthesia, speech disorder. Respiratory—pharyngitis, dyspnea. Skin and Appendages—fungal dermatitis. Special Senses—abnormal vision. ***Dose Dependency:*** An analysis for dose response in the schizophrenia trials revealed an apparent relation of adverse event to dose for the following: asthenia, postural hypotension, anorexia, dry mouth, increased salivation, arthralgia, anxiety, dizziness, dystonia, hypertonia, somnolence, tremor, rhinitis, rash, and abnormal vision. ***Extrapyramidal Symptoms (EPS):*** The incidence of reported EPS for GEODON patients in the short-term, placebo-controlled schizophrenia trials was 14% vs 8% for placebo. Objectively collected data from those trials on the Simpson-Angus Rating Scale and the Barnes Akathisia Scale did not generally show a difference between GEODON and placebo. ***Dystonia:*** Prolonged abnormal contractions of muscle groups may occur in susceptible individuals during first few days of treatment. Dystonia may occur at any dose level but with greater frequency and severity with high potency and at higher doses of first generation antipsychotic drugs. Elevated risk is observed in males and younger age groups. ***Vital Sign Changes:*** GEODON is associated with orthostatic hypotension (see **PRECAUTIONS**). ***Weight Gain:*** In short-term schizophrenia trials, the proportions of patients meeting a weight gain criterion of ≥7% of body weight were compared, revealing a statistically significantly greater incidence of weight gain for GEODON patients (10%) vs placebo patients (4%). A median weight gain of 0.5 kg was observed in GEODON patients vs 0.0 kg in placebo patients. Weight gain was reported as an adverse event in 0.4% of both GEODON and placebo patients. During long-term therapy with GEODON, a categorization of patients at baseline on the basis of body mass index (BMI) showed the greatest mean weight gain and the highest incidence of clinically significant weight gain (>7% of body weight) in patients with a low BMI (<23) compared to normal (23-27) or overweight (>27) patients. There was a mean weight gain of 1.4 kg for patients with a "low" baseline BMI, 0.0 kg for patients with a "normal" BMI, and a 1.3 kg mean weight loss for patients with a "high" BMI. ***ECG Changes:*** GEODON is associated with an increase in the QT_c interval (see **WARNINGS**). In schizophrenia trials, GEODON was associated with a mean increase in heart rate of 1.4 beats per minute compared to a 0.2 beats per minute decrease among placebo patients. ***Other Adverse Events Observed During the Premarketing Evaluation of GEODON:*** Frequent adverse events are those occurring in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients. Schizophrenia: Body as a Whole — *Frequent:* abdominal pain, flu syndrome, fever, accidental fall, face edema, chills, photosensitivity reaction, flank pain, hypothermia, motor vehicle accident. Cardiovascular System — *Frequent:* tachycardia, hypertension, postural hypotension; *Infrequent:* bradycardia, angina pectoris, atrial fibrillation; *Rare:* first-degree AV block, bundle branch block, phlebitis, pulmonary embolus, cardiomegaly, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, myocarditis, thrombophlebitis. Digestive System — *Frequent:* anorexia, vomiting; *Infrequent:* rectal hemorrhage, dysphagia, tongue edema; *Rare:* gum hemorrhage, jaundice, fecal impaction, gamma glutamyl transpeptidase increased, hematemesis, cholestatic jaundice, hepatitis, hepatomegaly, leukoplakia of mouth, fatty liver deposit, melena. Endocrine — *Rare:* hypothyroidism, hyperthyroidism, thyroiditis. Hemic and Lymphatic System — *Infrequent:* anemia, ecchymosis, leukocytosis, leukopenia, eosinophilia, lymphadenopathy; *Rare:* thrombocytopenia, hypochromic anemia, lymphocytosis, monocytosis, basophilia, lymphedema, polycythemia, thrombocythemia. Metabolic and Nutritional Disorders — *Infrequent:* thirst, transaminase increased, peripheral edema, hyperglycemia, creatine phosphokinase increased, alkaline phosphatase increased, hypercholesteremia, dehydration, lactic dehydrogenase increased, albuminuria, hypokalemia; *Rare:* BUN increased, creatinine increased, hyperlipemia, hypocholesteremia, hyperkalemia, hypochloremia, hypoglycemia, hyponatremia, hypoproteinemia, glucose tolerance decreased, gout, hyperchloremia, hyperuricemia, hypocalcemia, hypoglycemic reaction, hypomagnesemia, ketosis, respiratory alkalosis. Musculoskeletal System — *Frequent:* myalgia; *Infrequent:* tenosynovitis; *Rare:* myopathy. Nervous System — *Frequent:* agitation, extrapyramidal syndrome, tremor, dystonia, hypertonia, dyskinesia, hostility, twitching, paresthesia, confusion, vertigo, hypokinesia, hyperkinesia, abnormal gait, oculogyric crisis, hypesthesia, ataxia, amnesia, cogwheel rigidity, delirium, hypotonia, akinesia, dysarthria, withdrawal syndrome, buccoglossal syndrome, choreoathetosis, diplopia, incoordination, neuropathy; *Infrequent:* paralysis; *Rare:* myoclonus, nystagmus, torticollis, circumoral paresthesia, opisthotonos, reflexes increased, trismus. Respiratory System — *Frequent:* dyspnea; *Infrequent:* pneumonia, epistaxis; *Rare:* hemoptysis, laryngismus. Skin and Appendages — *Infrequent:* maculopapular rash, urticaria, alopecia, eczema, exfoliative dermatitis, contact dermatitis, vesiculobullous rash. Special Senses — *Frequent:* fungal dermatitis; *Infrequent:* conjunctivitis, dry eyes, tinnitus, blepharitis, cataract, photophobia; *Rare:* eye hemorrhage, visual field defect, keratitis, keratoconjunctivitis. Urogenital System — *Infrequent:* impotence, abnormal ejaculation, amenorrhea, hematuria, menorrhagia, female lactation, polyuria, urinary retention, metrorrhagia, male sexual dysfunction, anorgasmia, glycosuria; *Rare:* gynecomastia, vaginal hemorrhage, nocturia, oliguria, female sexual dysfunction, uterine hemorrhage. **Adverse Finding Observed in Trials of Intramuscular GEODON:** In these studies, the most commonly observed adverse events associated with the use of intramuscular GEODON (≥5%) and observed at a rate on intramuscular GEODON (in the higher dose groups) at least twice that of the lowest intramuscular GEODON group were headache (13%), nausea (12%), and somnolence (20%). **Adverse Events at an Incidence >1% in Short-Term Fixed-Dose Intramuscular Trials:** The following list enumerates the treatment-emergent adverse events that occurred in ≥1% of GEODON patients (in the higher dose groups) and at least twice that of the lowest intramuscular GEODON group. Body as a Whole — headache, injection site pain, asthenia, abdominal pain, flu syndrome, back pain. Cardiovascular — postural hypotension, hypertension, bradycardia, vasodilation. Digestive — nausea, rectal hemorrhage, diarrhea, vomiting, dyspepsia, anorexia, constipation, tooth disorder, dry mouth. Nervous — dizziness, anxiety, insomnia, somnolence, akathisia, agitation, extrapyramidal syndrome, hypertonia, cogwheel rigidity, paresthesia, personality disorder, psychosis, speech disorder. Respiratory — rhinitis. Skin and Appendages — furunculosis, sweating. Urogenital — dysmenorrhea, priapism. **DRUG ABUSE AND DEPENDENCE — *Controlled Substance Class:*** GEODON is not a controlled substance. **OVERDOSAGE** — In premarketing trials in over 5400 patients, accidental or intentional overdosage of GEODON was documented in 10 patients. All patients survived without sequelae. In the patient taking the largest confirmed amount (3240 mg), the only symptoms reported were minimal sedation, slurring of speech, and transitory hypertension (BP 200/95).

Revised August 2008

A new US distributor for books from the Royal College of Psychiatrists

RC PSYCH
ROYAL COLLEGE OF PSYCHIATRISTS

Mindreadings

Literature and Psychiatry

Edited by Femi Oyebode



Literature can be a medium for clarifying, examining and defining human emotions, behavior and thoughts. For psychiatrists, this means that literary texts can be valuable tools for furthering our understanding of patients and their conditions. The chapters in this book all explore the fruitful relationships between the written word and some central aspects of psychiatric practice. Some were originally published in the journal *Advances in Psychiatric Treatment* and some are newly commissioned.

ISBN 978-1-904671-60-2, paperback, 160 pages, January 2009, $30

Seminars in General Adult Psychiatry

Second edition

Edited by George Stein and Greg Wilkinson



A comprehensive account of modern adult psychiatry, this places emphasis on detailed clinical descriptions of both common and rare psychiatric disorders and their place within DSM–IV and ICD–10. Historical sections give access to both classic studies of psychiatry and current evidence. Clinical management is given due prominence, with extensive accounts of modern drug management, cognitive therapy, the main psychosocial approaches, and current guidelines. There are new chapters on liaison psychiatry, clinical epidemiology, psychosexual medicine, and international and cultural psychiatry. This readable volume is an essential text for psychiatric trainees. It is also a one-stop reference work for established practitioners.

ISBN 978-1-904671-44-2, hardback, 834 pages, 2007, $130

Am I Going to Die?

(From the *Books Beyond Words* series)

Sheila Hollins, Irene Tuffrey-Wijne and Amelia Jones.
Illustrated by Lisa Kopper



The *Books Beyond Words* series uses pictures to tell stories about difficult events or emotions. They are for use with people who have intellectual disabilities (also useful for those with literacy problems). Supporting text and guidelines are provided for carers and healthcare professionals, at the back of the books. There are 26 different titles in the series covering a wide variety of healthcare and independent living issues.

In this book, John has an intellectual disability and is terminally ill. His story deals honestly and movingly with both the physical deterioration and the emotional aspects of dying. As he gets weaker John looks back at his life, and chooses how to spend his remaining time. He dies at home among family and friends.

ISBN 978-1-904671-62-6, paperback, 112 pages, March 2009, $20

Seminars in the Psychotherapies

Edited by Jane Naismith and Sandra Grant



This book gives an overview of the major types of psychotherapy, including: psychodynamic theories and therapies; systemic therapy; cognitive-behavioral theories and therapies; and group and family therapy. It also covers assessment, research and training in psychotherapy.

ISBN 978-1-904671-45-9, paperback, 292 pages, 2007, $40

RCPsych Publications titles are now available from:
Publishers Storage and Shipping Company, 46 Development Road, Fitchburg, MA 01420.
Tel: 978 829 2560. Fax: 978 348 1233. Email: orders@pssc.com

Many titles can also be ordered through www.amazon.com

(RCPsych Publications is the name given to books produced by the Royal College of Psychiatrists in the UK. For our full list of over 140 titles see: www.rcpsych.ac.uk/publications)



Coming October 2009!

Dulcan's Textbook of Child and Adolescent Psychiatry

Edited by Mina K. Dulcan, M.D.

Special Prepublication Price of 215.00
until October 31, 2009 (thereafter $239.00)

Dulcan's Textbook of Child and Adolescent Psychiatry supplants the previous textbook edited by Jerry Wiener and Mina Dulcan—not with a new edition, but rather a new book that offers a fresh look at the field of child mental health. It preserves Wiener's vision of a clinically focused textbook useful to trainees and practitioners in a variety of specialties, providing the most up-to-date and comprehensive text in child and adolescent psychiatry as presented by more than 110 contributors who distill their knowledge and expertise into a single authoritative volume.

Each chapter highlights what we know about evidence-based practices in assessment and treatment, while sections on future research point toward current pressing questions. At the end of each chapter are educational summary points. Of the 65 chapters, 56 feature new lead authors, chosen to represent the expertise of disciplines ranging from pediatrics and neurology to sleep medicine and family therapy.

Among its key features:

- Chapters on evaluation are developmentally focused, with a separate chapter for each age range.
- The section on diagnosis and assessment has been reconfigured and includes a new chapter on neurological examination and the use of EEG and imaging.
- Eighteen chapters on specific disorders encompass clinical description, diagnosis, epidemiology, comorbidity, etiology, prevention, prognosis, evaluation, treatment approaches, and research directions.
- Special topics include new chapters on bereavement and traumatic grief; ethnic, cultural, and religious issues; aggression and violence; and fundamentals of genetics relevant to child and adolescent psychiatry.
- Additional chapters address special clinical considerations such as children of ill parents AND legal/ethical issues
- Wide-ranging emphasis on treatment—expanded from seven to eighteen chapters—includes psychopharmacology, brain-based innovative treatments, and a spectrum of psychosocial approaches that focus on individual, family, therapeutic milieu, and systemic models of care.
- A new section on consultation provides guidance on interactions with schools, primary care practitioners, and the juvenile justice system.

Scholarly and practical, *Dulcan's Textbook of Child and Adolescent Psychiatry* is a core resource for child and adolescent psychiatry training and will also serve as a reference for practitioners in psychiatry, pediatrics, neurology, psychology, nursing, and social work.

American Psychiatric Publishing, Inc.
The *First* and *Last* Word in Psychiatry

2010 • 1,104 pages • ISBN 978-1-58562-323-5 • Hardcover • Item #62323
Special Prepublication Price of $215.00 until October 31, 2009 (thereafter $239.00)

Order Online: www.appi.org • Toll Free: 1-800-368-5777
Fax: 703-907-1091 • Email: appi@psych.org • Find us on Facebook and Twitter. AH938

Enjoy Quality of Life…Practice Quality Medicine…

McLeod Health Behavioral Health Psychiatric Center is located in the beautiful southern town of Darlington, SC- a quick 45 minute drive to our state capital, Columbia, SC, and a 2 Hour drive to Charleston, SC and Charlotte, NC. We are looking for two BC/BE Psychiatrists with an innovative approach to medicine. Duties will include inpatient, outpatient, and Consult Services. Depending on the Physician's strengths, the Physician will perform any combination of these duties. Other features of the position include:

Flexible schedule with limited call

New state of the art facility with 23 inpatient beds

24 hour Access Center with an experienced staff

Great potential for program growth and development

We offer a competitive salary, comprehensive benefits and retirement package, paid time off, paid professional liability insurance, CME allowance, relocation assistance, and sign on bonus.

McLeod is a leader in the healthcare industry. We are committed to developing patient-centered, evidence-based, physician-led, quality health care in a not-for-profit hospital system that values each individual patient.

Don't miss an opportunity to become a staff physician with the leader in healthcare! Please contact Tiffany Ellington, Director of Physician Recruitment, at mcleodphysicianrecruiting.com or 843-777-5169.

Department of Veterans Affairs

Director of Residency Training

Harvard South Shore Psychiatry Residency Training Program
Department of Psychiatry Harvard Medical School
&
The VA Boston Healthcare System

Harvard Medical School and the VA Boston Healthcare System are recruiting a Training Director for the Harvard South Shore Psychiatry Residency Training Program (HSS). The Harvard Department of Psychiatry at the VA Boston Healthcare System has undergone a major expansion of teaching, research, and academic clinical programming over the past two years. The current Training Director is assuming the duties of Departmental Chair for Academic Development, which will include ongoing support to HSS including teaching, supervision, and consultative support to the incoming Training Director.

HSS is a consortium program affiliated with Harvard Medical School and sponsored by the VA Boston Healthcare System. Residents rotate among three Boston VA campuses, other Harvard-affiliated training hospitals, and Massachusetts Department of Mental Health facilities. HSS receives stable funding for 32 PGY I-IV resident positions plus ample administrative support, not dependent on GME pass-through funding. Major foci of program excellence include biopsychosocial assessment and interviewing skills, academic development in research, teaching and leadership, evidence-based pharmacotherapy, and manual-guided psychotherapies. Comprehensive program description can be found at **www.harvardsouthshorepsychiatry.org.**

The competitive Training Director candidate will have strong academic credentials, residency administration experience at the site or program level, and demonstrated scholarly ability in a relevant field. The applicant must be board-certified in psychiatry with a minimum of 5 years of post-residency experience, and is expected to qualify for a Harvard Medical School appointment at the Assistant or Associate Professor level.

This position offers a highly competitive federal salary and benefits. VA Boston is an Affirmative Action / Equal Opportunity Employer, and women and individuals from health-underserved minority populations are encouraged to apply.

To apply, candidates should send a letter of interest, CV, and the names of three persons to contact for references to:

Drs. Mark Bauer & Gary Kaplan, Search Committee Co-Chairs
940 Belmont Street, Brockton, MA 02301; or email materials to:
Eugene.Francois@va.gov with a copy to vhabhsjobs@med.va.gov

Patient Centered
Care Focused

Assistant Medical Director Behavioral Health – Inpatient Care

HealthPartners Medical Group is a top multi-specialty group based in Minneapolis/St. Paul, Minnesota. Regions Hospital is our busy NAMI "Provider of the Year" hospital in St. Paul, home to our ER-based short-stay psychiatric unit and inpatient psychiatric facilities.

We are recruiting for an Inpatient Behavioral Health Medical Director at Regions Hospital. In addition to maintaining substantive patient care responsibilities, this consensus-building leader will measure and improve quality of inpatient psychiatric care and patient flow; oversee our Psychiatric Consultation & Liaison Service; engage and supervise Regions Hospital inpatient psychiatrists, moonlighters and Advanced Practice Providers; develop and implement inpatient mental health policies/procedures; and ensure hospital regulatory requirements are met (JCAHO, CMS, MN DMS, etc.). In addition, there will be a substantial role with our psychiatric residents, medical students and NP/PA fellows.

Qualified candidates will have at least two (2) years' experience leading and motivating hospital-based Inpatient Behavioral Health care teams, and at least five (5) years recent inpatient practice experience. Board Certification in Psychiatry and active, valid MN medical licensure are required. We offer a competitive compensation and benefits package, paid malpractice coverage, and a rewarding work environment.

Forward your CV and cover letter to **lori.m.fake@healthpartners.com** or apply online at **www.healthpartners.jobs**. Call (800) 472-4695 x1 for more information. EOE

HealthPartners®
Medical Group

www.healthpartners.com
www.regionshospital.com

Department of Veterans Affairs

Psychiatrists - VA Boston Healthcare System

The VA Boston Healthcare System (VABHS) is recruiting academically oriented psychiatrists for a number of key positions in our growing Mental Health Service, which has strong and longstanding affiliations with Harvard Medical School (HMS) and Boston University School of Medicine (BUSM) and major campuses located in Boston (Jamaica Plain and West Roxbury) and Brockton. VABHS is a New England regional referral center for veterans' health care.

Medical Director, Consultation-Liaison Psychiatry

West Roxbury campus:

VABHS is recruiting a Medical Director for the Psychiatry Consultation-Liaison service, West Roxbury campus. We seek a board certified academic psychiatrist with at least 5 years' post-residency experience full time (or equivalent) on an academic C-L service, demonstrated excellence in clinical teaching, strong administrative skills, and the motivation and ability to lead this outstanding clinical teaching service. The C-L service receives more than 1200 consultation requests per year, and is an integral part of a vibrant and exceptional academic environment that features nationally recognized training and research programs, and several VA Clinical Centers of Excellence. Academic appointment is through HMS, commensurate with qualifications. The Medical Director oversees the VA-Brigham Women's Hospital Psychosomatic Fellowship and BUSM and HMS resident and medical student C-L rotations. *If you are interested in this position, please send a letter of interest, CV, and contact information for three references to:* **Gary B. Kaplan, M.D., Director, Mental Health Service, VA Boston Healthcare System, 940 Belmont Street, Brockton, MA 02301. Email: Gary.Kaplan@va.gov with a copy to: vhabhsjobs@med.va.gov**

Inpatient/Outpatient Psychiatrist

Brockton campus:

VABHS is recruiting a full-time board-certified (board eligible if less than 2 years post-residency) psychiatrist with a demonstrated commitment to academic psychiatry. This position is divided evenly between inpatient and outpatient programs. Inpatient duties: The psychiatrist will join a well-staffed multidisciplinary inpatient treatment team (7 psychiatrists, 3 psychiatry nurse practitioners, 4 psychologists and 4 social workers) to provide direct clinical services to our acutely ill patient population. The inpatient service has had a major transformation and expansion of its clinical staffing the past year to support the academic and clinical mission of the medical center. Outpatient duties: The psychiatrist will join a vibrant multidisciplinary PTSD treatment team (1 psychiatrist, three psychologists and four social workers) that provides evidence-based clinical care to veterans of all eras including a large cohort of veterans who have recently returned from Iraq and Afghanistan. Duties include support of the academic mission of the medical center, including supervision of psychiatry residents and the opportunity to participate in teaching and research. This position offers a highly competitive VA salary and a faculty appointment at Harvard Medical School commensurate with experience. *If you are interested in this position, please send a letter of interest, CV, and contact information for three references to:* **Gary B. Kaplan, M.D., Director, Mental Health Service, VA Boston Healthcare System, 940 Belmont Street, Brockton, MA 02301. Email: Gary.Kaplan@va.gov with a copy to vhabhsjobs@med.va.gov**

Emergency Department Moonlighting Positions

Brockton Campus:

VABHS is recruiting board certified (board eligible if less than 5 years post-residency) psychiatrists to provide direct clinical services and clinical supervision of psychiatry residents on evenings and weekends in the Urgent Care Department on our Brockton campus. In addition to an outstanding academic environment, this position offers competitive compensation and the possibility of an academic appointment for qualified individuals. Hours are 4pm-11pm weekdays and 7am-3pm or 3pm-11pm on Saturdays and Sundays. Please send a letter of interest, CV, and contact information for three references to: **Dr. Ronald Gurrera, Director of Urgent Care Services, Mental Health Service, VA Boston Healthcare System, 940 Belmont Street, Brockton, MA 02301. Phone: 774-826-2473; Email: Ronald.Gurrera@va.gov with a copy to: vhabhsjobs@med.va.gov**

VA Boston is an Affirmative Action/Equal Opportunity Employer with a strong institutional commitment to diversity in all areas. These positions will be filled without discrimination. You must be a U.S. citizen to apply.

DIRECTOR of CHILD and ADOLESCENT PSYCHIATRY (Tenure-Track)

State University of New York
Upstate Medical University, Syracuse

The Department of Psychiatry at SUNY Upstate Medical University is seeking an outstanding Director for its flourishing Division of Child and Adolescent Psychiatry. The Division has a regional reputation for excellence in clinical care and education, a fellowship training program, telepsychiatry, expanding clinical programs, and internationally acclaimed researchers, including Drs. Faraone, Barkley, Kates, Gordon, Fremont, Staller and Glatt, who receive over $3 million in NIH funding each year. SUNY Upstate encompasses a major medical school, a graduate school, research facilities, and a new Children's Hospital.

This is a tenure-track position at the rank of Associate or Full Professor. Candidates must have an established national reputation as an academic leader having a record of accomplishment in clinical care and education. Experience with funded research is preferred but not required. Candidates must possess mentoring and leadership skills necessary for faculty development and advancement of the Division.

The rolling hills of Upstate New York boast excellent schools, low cost of living, several major liberal arts colleges and universities, and numerous recreational and entertainment opportunities.

For a prompt and confidential review, please apply on-line to job #024651 via the SUNY Upstate Human Resources website **jobs.upstate.edu**, **or for information only, please contact Jean Pollock at (315) 464-3105 or pollockj@upstate.edu**.

State University of New York
Upstate Medical University

An AA/EEO/ADA employer engaging excellence through diversity.

Atascadero State Hospital

BE/BC Psychiatrist

Atascadero State Hospital now pays board certified psychiatrists starting at $223,464 and advancing stepwise to $255,732. Atascadero is the nation's premier center for the treatment of forensically committed mentally ill patients. Our hospital is a teaching site affiliated with the University of California, accredited by JCAHO, and recipient of the prestigious Codman Award. All of our psychiatrists are board eligible and most are board certified. Many of our psychiatrists have forensic subspecialty boards.

We are located midway between San Francisco and Los Angeles on the scenic central California Coast, south of Big Sur. We offer a spectacularly beautiful environment in San Luis Obispo County with temperate climate, beaches, world class wineries, cultural activities, golfing, sailing, riding, clean air, and excellent schools through the University level.

Our benefit package is valued at an additional 30%, which includes retirement plans (including safety retirement), health plans, professional liability coverage, paid holidays, educational leave, and generous annual leave. On-call duty is compensated hour for hour over and above the base salary. Applicants must hold a current California license, or have pending application with the Medical Board of California.

For a prompt and confidential review, send CV to:

Jeanne Garcia, M.D.
P. O. Box 7001
Atascadero, CA 93423-7001
(805) 468-2005 or fax (805) 468-2138
or e-mail us: jeanne.garcia@ash.dmh.ca.gov

WE ARE AN EQUAL OPPORTUNITY EMPLOYER.

SINCE 1907

ROGERS MEMORIAL HOSPITAL℠

MEDICAL DIRECTOR CHEMICAL DEPENDENCY

Leadership opportunity for ASAM board-certified psychiatrist at Wisconsin's largest private, not-for-profit provider of behavioral health services.

Ideal candidate will posses a passion for patient-centered care, enthusiasm for collaboration, and a proven history of favorable treatment outcomes.

- Participate in the hospital's full continuum of chemical dependency services
- Provide direction for the residential program at **The Herrington Recovery Center**
- Enjoy a competitive, guaranteed salary, equitable call schedule, compensation package
- Benefit from an environment of open collaboration and ongoing development
- Work at southeastern Wisconsin's largest private, not-for-profit provider of inpatient and residential behavioral health care services

CHILD AND ADOLESCENT PSYCHIATRIST

Extraordinary opportunity for BE/BC psychiatrist. Participate in **Roger Memorial Hospital's** full continuum of child and adolescent behavioral health care services. This position's primary responsibilities are related to the delivery of compassionate care for inpatient youths.

Be part of a multidisciplinary team that helps families manage their children's challenges through the use of evidence-based treatment methods.

Ideal candidate will posses a passion for patient-centered care and a desire to represent and support the values and visions of Rogers Memorial Hospital.

- Enjoy a competitive, guaranteed salary, equitable call schedule, compensation package
- Benefit from an environment of open collaboration and ongoing development
- Work at southeastern Wisconsin's largest private, not-for-profit provider of inpatient and residential behavioral health care services

www.rogershospital.org

Send CV and letter of interest to:
medstaff@rogershospital.org

OR MAIL TO:
Medical Staff Office • Rogers Memorial Hospital
34700 Valley Road • Oconomowoc, WI 53066

Phone: 262-646-1391
Fax: 262-646-1393

APA JOB BANK

Use the APA Job Bank's *Conference Connection* tool to set up interviews at the Institute on Psychiatric Services

Sign up for the *Conference Connection* at the Institute on Psychiatric Services, October 8-11 in New York City, and let potential employers and candidates know that you will be attending the meeting.

Candidates

Access the most comprehensive listing of psychiatric positions and find your ideal position at the APA Job Bank at psych.org/jobbank. Register to use the *Conference Connection*, post your resume, receive instant job alerts, use the career tools and more.

Employers

Use the many resources of the APA Job Bank at psych.org/jobbank to meet qualified candidates and make a smart recruitment decision. Advertise in the *Psychiatric Services* and/or *Psychiatric News* classifieds and the APA Job Bank and receive a 10% discount on each. Reach more psychiatrists at the Institute on Psychiatric Services with our bonus distribution of the *Psychiatric Services* October issue (deadline 9/3) and the *Psychiatric News* October 2 issue (deadline 9/4). For more information, contact Alice Kim at (703) 907-7330 or classads@psych.org

Candidates and Employers

During the meeting, stop by the APA Job Bank booth in the APA Member Center to search the database and ask a representative to demonstrate Job Bank features. The Institute on Psychiatric Services is the APA's leading educational conference on clinical issues and community mental health—for more information, visit psych.org/ips

APA Member Center and Job Bank

Location:	Sheraton New York Hotel and Towers Metropolitan Room, 2nd floor	
Hours:	Thursday, October 8	1:30 p.m. - 5:45 p.m.
	Friday, October 9	9:30 a.m. - 12:00 p.m.
		1:30 p.m. - 5:45 p.m.
	Saturday, October 10	9:30 a.m. - 12:00 p.m.

Index to Advertisers
September 2009

The publication of an advertisement in this journal does not imply endorsement of the product or service by the American Psychiatric Association.

Subscription and Business Information

The American Journal of Psychiatry, ISSN 0002-953X, is published monthly by the American Psychiatric Association, 1000 Wilson Blvd., Suite 1825, Arlington, VA 22209-3901. Subscriptions (per year): individual $205.00, international $308.00. For additional subscription options, including single issues and student rates, please contact Customer Service at 1-800-368-5777 or email appi@psych.org. Institutional subscriptions are tier priced. For institutional site license or pricing information, contact Customer Service or visit http://highwire.stanford.edu/tfocis/.

Business communications, address changes, and subscription questions from APA members should be directed to the Division of Member Services: (888) 35-PSYCH (toll-free). Nonmember subscribers should call the Circulation Department (800) 368-5777. Author inquiries should be directed to the Journal editorial office: (703) 907-7885 or (703) 907-7884; fax (703) 907-1096; e-mail ajp@psych.org.

Business Management: Nancy Frey, Director, Publishing Services; Laura G. Abedi, Associate Director, Production; Alison Jones, Advertising Prepress Manager; Robert Pursell, Director, Sales and Marketing.

Pharmaceutical Print Advertising: Frank Cox, Kathleen Harrison, Valentin Torres, Pharmaceutical Media, Inc. 30 East 33rd Street, New York, NY 10016. (212) 685-5010; fax (212) 685-6126; e-mail vtorres@pminy.com.

Nonpharmaceutical and Online Sales: Brian Skepton, (703) 907-7332; e-mail bskepton@psych.org.

Pages are produced using Adobe FrameMaker+ SGML 6.0. Printed by RR Donnelley, Mendota, IL., on acid-free paper effective with Volume 164, Number 11, November 2007.

Periodicals postage paid at Arlington, VA, and additional mailing offices. POSTMASTER: Send address changes to The American Journal of Psychiatry, Circulation Department, American Psychiatric Association, 1000 Wilson Blvd., Suite 1825, Arlington, VA 22209-3901.

Indexed in Abstracts for Social Workers, Academic Abstracts, Biological Abstracts, Chemical Abstracts, Chicago Psychoanalytic Literature Index, Cumulative Index to Nursing Literature, Excerpta Medica, Hospital Literature Index, Index Medicus, International Nursing Index, Nutrition Abstracts, Psychological Abstracts, Science Citation Index, Social Science Source, and Social Sciences Index.

dose-dependent increase in the proportion of patients who developed sustained hypertension. **Abnormal Bleeding-** SSRIs and SNRIs can increase the risk of bleeding events. Concomitant use of aspirin, other drugs that affect platelet function, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants can add to this risk. Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages. Patients should be cautioned about the risk of bleeding associated with the concomitant use of Pristiq and NSAIDs, aspirin, or other drugs that affect coagulation or bleeding. **Narrow-angle Glaucoma-**Mydriasis has been reported in association with Pristiq; therefore, patients with raised intraocular pressure or those at risk of acute narrow-angle glaucoma (angle-closure glaucoma) should be monitored. **Activation of Mania/Hypomania-**During all MDD and VMS (vasomotor symptoms) phase 2 and phase 3 studies, mania was reported for approximately 0.1% of patients treated with Pristiq. Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorder who were treated with other marketed antidepressants. As with all antidepressants, Pristiq should be used cautiously in patients with a history or family history of mania or hypomania. **Cardiovascular/Cerebrovascular Disease-**Caution is advised in administering Pristiq to patients with cardiovascular, cerebrovascular, or lipid metabolism disorders [see Adverse Reactions (6.1)]. Increases in blood pressure and heart rate were observed in clinical studies with Pristiq. Pristiq has not been evaluated systematically in patients with a recent history of myocardial infarction, unstable heart disease, uncontrolled hypertension, or cerebrovascular disease. Patients with these diagnoses, except for cerebrovascular disease, were excluded from clinical studies. **Serum Cholesterol and Triglyceride Elevation-** Dose-related elevations in fasting serum total cholesterol, LDL (low-density lipoprotein) cholesterol, and triglycerides were observed in the controlled studies. Measurement of serum lipids should be considered during treatment with Pristiq [see Adverse Reactions (6.1)]. **Discontinuation of Treatment with Pristiq-** Discontinuation symptoms have been systematically and prospectively evaluated in patients treated with Pristiq during clinical studies in major depressive disorder. Abrupt discontinuation or dose reduction has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis. In general, discontinuation events occurred more frequently with longer duration of therapy. During marketing of SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors) and SSRIs (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (eg, paresthesia, such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms. Patients should be monitored for these symptoms when discontinuing treatment with Pristiq. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate [see Dosage and Administration (2.4) and Adverse Reactions (6.1) in full prescribing information]. **Renal Impairment-**In patients with moderate or severe renal impairment or end-stage renal disease (ESRD) the clearance of Pristiq was decreased, thus prolonging the elimination half-life of the drug. As a result, there were potentially clinically significant increases in exposures to Pristiq [see Clinical Pharmacology (12.6) in full prescribing information]. Dosage adjustment (50 mg every other day) is necessary in patients with severe renal impairment or ESRD. The doses should not be escalated in patients with moderate or severe renal impairment or ESRD [see Dosage and Administration (2.2) in full prescribing information]. **Seizure-**Cases of seizure have been reported in premarketing clinical studies with Pristiq. Pristiq should be prescribed with caution in patients with a seizure disorder. **Hyponatremia-** Hyponatremia can occur as a result of treatment with SSRIs and SNRIs, including Pristiq. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Elderly patients can be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.6) in full prescribing information]. Discontinuation of Pristiq should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted. **Coadministration of Drugs Containing Desvenlafaxine and Venlafaxine-** Desvenlafaxine is the major active metabolite of venlafaxine. Products containing desvenlafaxine and products containing venlafaxine should not be used concomitantly with Pristiq. **Interstitial Lung Disease and Eosinophilic Pneumonia-** Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of Pristiq) therapy have been rarely reported. The possibility of these adverse events should be considered in patients treated with Pristiq who present with progressive dyspnea, cough, or chest discomfort. Such patients should undergo a prompt medical evaluation, and discontinuation of Pristiq should be considered.

ADVERSE REACTIONS: Clinical Studies Experience: The most commonly observed adverse reactions in Pristiq-treated MDD patients in short-term fixed-dose studies (incidence ≥5% and at least twice the rate of placebo in the 50- or 100-mg dose groups) were nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders. Adverse reactions reported as reasons for discontinuation of treatment- The most common adverse reactions leading to discontinuation in at least 2% of the Pristiq-treated patients in the short-term studies, up to 8 weeks, were nausea (4%); dizziness, headache and vomiting (2% each); in the long-term study, up to 9 months, the most common was vomiting (2%). Common adverse reactions in placebo-controlled MDD studies- Table 3 in full PI shows the incidence of common adverse reactions that occurred in ≥2% of Pristiq-treated MDD patients at any dose in the 8-week, placebo-controlled, fixed-dose, premarketing clinical studies. In general, the adverse reactions were most frequent in the first week of treatment. Cardiac disorders: Palpitations, Tachycardia, Blood pressure increased; Gastrointestinal disorders: Nausea, Dry mouth, Diarrhea, Constipation, Vomiting; General disorders and administration site conditions: Fatigue, Chills, Feeling jittery, Asthenia; Metabolism and nutrition disorders: Decreased appetite, weight decreased; Nervous system disorders: Dizziness, Somnolence, Headache, Tremor, Paraesthesia, Disturbance in attention; Psychiatric Disorders: Insomnia, Anxiety, Nervousness, Irritability, Abnormal dreams; Renal and urinary disorders: Urinary hesitation; Respiratory, thoracic, and mediastinal disorders: Yawning; Skin and subcutaneous tissue disorders: Hyperhidrosis, Rash; Special Senses: Vision blurred; Mydriasis, Tinnitus, Dysgeusia; Vascular Disorders: Hot flush. Sexual function adverse reactions-Table 4 shows the incidence of sexual function adverse reactions that occurred in ≥2% of Pristiq-treated MDD patients in any fixed-dose group (8-week, placebo-controlled, fixed and flexible-dose, premarketing clinical studies). Men Only: Anorgasmia, Libido decreased, Orgasm abnormal, Ejaculation delayed, Erectile dysfunction, Ejaculation disorder, Ejaculation failure, Sexual dysfunction; Women Only: Anorgasmia; Other adverse reactions observed in premarketing clinical studies: Other infrequent adverse reactions occurring at an incidence of <2% in MDD patients treated with Pristiq were: Immune system disorders – Hypersensitivity. Investigations – Liver function test abnormal, blood prolactin increased. Nervous system disorders – Convulsion, syncope, extrapyramidal disorder. Psychiatric disorders – Depersonalization, hypomania. Respiratory, thoracic and mediastinal disorders – Epistaxis. Vascular disorders – Orthostatic hypotension. In clinical studies, there were uncommon reports of ischemic cardiac adverse events, including myocardial ischemia, myocardial infarction, and coronary occlusion requiring revascularization; these patients had multiple underlying cardiac risk factors. More patients experienced these events during Pristiq treatment as compared to placebo [see Warnings and Precautions (5.7)]. Discontinuation events-Adverse events reported in association with abrupt discontinuation, dose reduction or tapering of treatment in MDD clinical studies at a rate of ≥5% include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, abnormal dreams, fatigue, and hyperhidrosis. In general, discontinuation events occurred more frequently with longer duration of therapy [see Dosage and Administration (2.4) and Warnings and Precautions (5.9) in full prescribing information]. Laboratory, ECG and vital sign changes observed in MDD clinical studies-The following changes were observed in placebo-controlled, short-term, premarketing MDD studies with Pristiq. Lipids-Elevations in fasting serum total cholesterol, LDL (low-density lipoprotein) cholesterol, and triglycerides occurred in the controlled studies. Some of these abnormalities were considered potentially clinically significant [see Warnings and Precautions (5.8)]. Proteinuria-Proteinuria, greater than or equal to trace, was observed in the fixed-dose controlled studies (see Table 6 in full prescribing information). This proteinuria was not associated with increases in BUN or creatinine and was generally transient. ECG changes-Electrocardiograms were obtained from 1,492 Pristiq-treated patients with major depressive disorder and 984 placebo-treated patients in clinical studies lasting up to 8 weeks. No clinically relevant differences were observed between Pristiq-treated and placebo-treated patients for QT, QTc, PR, and QRS intervals. In a thorough QTc study with prospectively determined criteria, desvenlafaxine did not cause QT prolongation. No difference was observed between placebo and desvenlafaxine treatments for the QRS interval. Vital sign changes-Table 7 summarizes the changes that were observed in placebo-controlled, short-term, premarketing studies with Pristiq in patients with MDD (doses 50 to 400 mg). Relative to placebo, Pristiq was associated with mean increase of up to 2.1 mm Hg in systolic blood pressure, 2.3 mm Hg in diastolic blood pressure, and 4.1 bpm with supine pulse. At the final on-therapy assessment in the 6-month, double-blind, placebo-controlled phase of a long-term study in patients who had responded to Pristiq during the initial 12-week, open-label phase, there was no statistical difference in mean weight gain between Pristiq- and placebo-treated patients. Orthostatic hypotension- In the short-term, placebo-controlled clinical studies with doses of 50-400 mg, systolic orthostatic hypotension (decrease ≥30 mm Hg from supine to standing position) occurred more frequently in patients ≥65 years of age receiving Pristiq (8.0%, 7/87) versus placebo (2.5%, 1/40), compared to patients <65 years of age receiving Pristiq (0.9%, 18/1,937) versus placebo (0.7%, 8/1,218). **DRUG INTERACTIONS: Central Nervous System (CNS)-Active Agents-**The risk of using Pristiq in combination with other CNS-active drugs has not been systematically evaluated. Consequently, caution is advised when Pristiq is taken in combination with other CNS-active drugs [see Warnings and Precautions (5.13)]. **Monoamine Oxidase Inhibitors (MAOIs)-** Adverse reactions, some of which were serious, have been reported in patients who have recently been discontinued from a monoamine oxidase inhibitor (MAOI) and started on antidepressants with pharmacological properties similar to Pristiq (SNRIs or SSRIs), or who have recently had SNRI or SSRI therapy discontinued prior to initiation of an MAOI [see Contraindications (4.2)]. **Serotonergic Drugs-** Based on the mechanism of action of Pristiq and the potential for serotonin syndrome, caution is advised when Pristiq is coadministered with other drugs that may affect the serotonergic neurotransmitter systems [see Warnings and Precautions (5.2)]. **Drugs that Interfere with Hemostasis (eg, NSAIDs, Aspirin, and Warfarin)-** Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of case-control and cohort design have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding. These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs and SNRIs are coadministered with warfarin. Patients receiving warfarin therapy should be carefully monitored when Pristiq is initiated or discontinued. **Ethanol-** A clinical study has shown that desvenlafaxine does not increase the impairment of mental and motor skills caused by ethanol. However, as with all CNS-active drugs, patients should be advised to avoid alcohol consumption while taking Pristiq. **Potential for Other Drugs to Affect Desvenlafaxine-**Inhibitors of CYP3A4 (ketoconazole)- CYP3A4 is a minor pathway for the metabolism of Pristiq. Concomitant use of Pristiq with potent inhibitors of CYP3A4 may result in higher concentrations of Pristiq. Inhibitors of other CYP enzymes- Based on in vitro data, drugs that inhibit CYP isozymes 1A1, 1A2, 2A6, 2D6, 2C8, 2C9, 2C19, and 2E1 are not expected to have significant impact on the pharmacokinetic profile of Pristiq. **Potential for Desvenlafaxine to Affect Other Drugs-** Drugs metabolized by CYP2D6 (desipramine)- In vitro studies showed minimal inhibitory effect of desvenlafaxine on CYP2D6. Clinical studies have shown that desvenlafaxine does not have a clinically relevant effect on CYP2D6 metabolism at the dose of 100 mg daily. Concomitant use of desvenlafaxine with a drug metabolized by CYP2D6 can result in higher concentrations of that drug. Drugs metabolized by CYP3A4 (midazolam)- In vitro, desvenlafaxine does not inhibit or induce the CYP3A4 isozyme. Concomitant use of Pristiq with a drug metabolized by CYP3A4 can result in lower exposures to that drug. Drugs metabolized by CYP1A2, 2A6, 2C8, 2C9 and 2C19- In vitro, desvenlafaxine does not inhibit CYP1A2, 2A6, 2C8, 2C9, and 2C19 isozymes and would not be expected to affect the pharmacokinetics of drugs that are metabolized by these CYP isozymes. **P-glycoprotein Transporter-** In vitro, desvenlafaxine is not a substrate or an inhibitor for the P-glycoprotein transporter. The pharmacokinetics of Pristiq are unlikely to be affected by drugs that inhibit the P-glycoprotein transporter, and desvenlafaxine is not likely to affect the pharmacokinetics of drugs that are substrates of the P-glycoprotein transporter. **Electroconvulsive Therapy-** There are no clinical data establishing the risks and/or benefits of electroconvulsive therapy combined with Pristiq treatment. **USE IN SPECIFIC POPULATIONS: Pregnancy-** Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy. Teratogenic effects– Pregnancy Category C- There are no adequate and well-controlled studies of Pristiq in pregnant women. Therefore, Pristiq should be used during pregnancy only if the potential benefits justify the potential risks. Non-teratogenic effects- Neonates exposed to SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), or SSRIs (Selective Serotonin Reuptake Inhibitors), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome [see Warnings and Precautions (5.2)]. When treating a pregnant woman with Pristiq during the third trimester, the physician should carefully consider the potential risks and benefits of treatment [see Dosage and Administration (2.2)]. **Labor and Delivery-** The effect of Pristiq on labor and delivery in humans is unknown. Pristiq should be used during labor and delivery only if the potential benefits justify the potential risks. **Nursing Mothers-** Desvenlafaxine (O-desmethylvenlafaxine) is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from Pristiq, a decision should be made whether or not to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Only administer Pristiq to breastfeeding women if the expected benefits outweigh any possible risk. **Pediatric Use-** Safety and effectiveness in the pediatric population have not been established [see Box Warning and Warnings and Precautions (5.1)]. Anyone considering the use of Pristiq in a child or adolescent must balance the potential risks with the clinical need. **Geriatric Use-** Of the 3,292 patients in clinical studies with Pristiq, 5% were 65 years of age or older. No overall differences in safety or efficacy were observed between these patients and younger patients; however, in the short-term, placebo-controlled studies, there was a higher incidence of systolic orthostatic hypotension in patients ≥65 years of age compared to patients <65 years of age treated with Pristiq [see Adverse Reactions (6)]. For elderly patients, possible reduced renal clearance of desvenlafaxine should be considered when determining dose [see Dosage and Administration (2.2) and Clinical Pharmacology (12.6)]. If Pristiq is poorly tolerated, every other day dosing can be considered. SSRIs and SNRIs, including Pristiq, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event [see Warnings and Precautions (5.12)]. Greater sensitivity of some older individuals cannot be ruled out. **Renal Impairment-** In subjects with renal impairment the clearance of Pristiq was decreased. In subjects with severe renal impairment (24-hr CrCl < 30 mL/min) and end-stage renal disease, elimination half-lives were significantly prolonged, increasing exposures to Pristiq; therefore, dosage adjustment is recommended in these patients [see Dosage and Administration (2.2) and Clinical Pharmacology (12.6) in the full prescribing information]. **Hepatic Impairment-** The mean $t_{1/2}$ changed from approximately 10 hours in healthy subjects and subjects with mild hepatic impairment to 13 and 14 hours in moderate and severe hepatic impairment, respectively. No adjustment in starting dosage is necessary for patients with hepatic impairment.

OVERDOSAGE: Human Experience with Overdosage- There is limited clinical experience with desvenlafaxine succinate overdosage in humans. In premarketing clinical studies, no cases of fatal acute overdose of desvenlafaxine were reported. The adverse reactions reported within 5 days of an overdose > 600 mg that were possibly related to Pristiq included headache, vomiting, agitation, dizziness, nausea, constipation, diarrhea, dry mouth, paresthesia, and tachycardia. Desvenlafaxine (Pristiq) is the major active metabolite of venlafaxine. Overdose experience reported with venlafaxine (the parent drug of Pristiq) is presented below; the identical information can be found in the Overdosage section of the venlafaxine package insert. In postmarketing experience, overdose with venlafaxine (the parent drug of Pristiq) has occurred predominantly in combination with alcohol and/or other drugs. The most commonly reported events in overdosage include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis, seizures, and vomiting. Electrocardiogram changes (eg, prolongation of QT interval, bundle branch block, QRS prolongation), sinus and ventricular tachycardia, bradycardia, hypotension, rhabdomyolysis, vertigo, liver necrosis, serotonin syndrome, and death have been reported. Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants. Epidemiological studies have shown that venlafaxine-treated patients have a higher pre-existing burden of suicide risk factors than SSRI-treated patients. The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdosage, as opposed to some characteristic(s) of venlafaxine-treated patients, is not clear. Prescriptions for Pristiq should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose. **Management of Overdosage-** Treatment should consist of those general measures employed in the management of overdosage with any SSRI/SNRI. Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Activated charcoal should be administered. Induction of emesis is not recommended. Because of the moderate volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidotes for desvenlafaxine are known. In managing an overdose, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose. Telephone numbers for certified poison control centers are listed in the Physicians Desk Reference (PDR®).

This brief summary is based on Pristiq Prescribing Information W10529C004, revised February 2009.

Wyeth®

254223-01

For the treatment of adults with major depressive disorder

The start is just the beginning

It's not just about starting your adult patients with MDD on therapy; it's about helping them toward their treatment goals. Patients should be periodically reassessed to determine the need for continued treatment.[1]

PRISTIQ 50 mg:

- **SNRI therapy with efficacy proven in 8-week clinical studies**
- **One recommended therapeutic dose from the start**
- **Discontinuation rate due to adverse events comparable to placebo in 8-week clinical studies[1]**

Pristiq® desvenlafaxine 50 mg

think beyond start™

IMPORTANT TREATMENT CONSIDERATIONS

PRISTIQ 50-mg Extended-Release Tablets are indicated for the treatment of major depressive disorder in adults.

WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of PRISTIQ or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. PRISTIQ is not approved for use in pediatric patients.

Contraindications

- PRISTIQ is contraindicated in patients with a known hypersensitivity to PRISTIQ or venlafaxine.
- PRISTIQ must not be used concomitantly with an MAOI or within 14 days of stopping an MAOI. Allow 7 days after stopping PRISTIQ before starting an MAOI.

Warnings and Precautions

- **All patients treated with antidepressants should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of treatment and when changing the dose.** Consider changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or includes symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania, or suicidality that are severe, abrupt in onset, or were not part of the patient's presenting symptoms. **Families and caregivers of patients being treated with antidepressants should be alerted about the need to monitor patients.**
- Development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome-like reactions have been reported with SNRIs and SSRIs alone, including PRISTIQ treatment, but particularly with concomitant use of serotonergic drugs, including triptans, with drugs that impair the metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. If concomitant use with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. Concomitant use of PRISTIQ with serotonin precursors is not recommended.
- Patients receiving PRISTIQ should have regular monitoring of blood pressure since sustained increases in blood pressure were observed in clinical studies. Pre-existing hypertension should be controlled before starting PRISTIQ. Caution should be exercised in treating patients with pre-existing hypertension or other underlying conditions that might be compromised by increases in blood pressure. Cases of elevated blood pressure requiring immediate treatment have been reported. For patients who experience a sustained increase in blood pressure, either dose reduction or discontinuation should be considered.
- SSRIs and SNRIs, including PRISTIQ, may increase the risk of bleeding events. Concomitant use of aspirin, NSAIDs, warfarin, and other anticoagulants may add to this risk.
- Mydriasis has been reported in association with PRISTIQ; therefore, patients with raised intraocular pressure or those at risk of acute narrow-angle glaucoma (angle-closure glaucoma) should be monitored.
- PRISTIQ is not approved for use in bipolar depression. Prior to initiating treatment with an antidepressant, patients should be adequately screened to determine the risk of bipolar disorder.
- As with all antidepressants, PRISTIQ should be used cautiously in patients with a history or family history of mania or hypomania, or with a history of seizure disorder.
- Caution is advised in administering PRISTIQ to patients with cardiovascular, cerebrovascular, or lipid metabolism disorders. Increases in blood pressure and small increases in heart rate were observed in clinical studies with PRISTIQ. PRISTIQ has not been evaluated systematically in patients with a recent history of myocardial infarction, unstable heart disease, uncontrolled hypertension, or cerebrovascular disease.
- Dose-related elevations in fasting serum total cholesterol, LDL (low density lipoprotein) cholesterol, and triglycerides were observed in clinical studies. Measurement of serum lipids should be considered during PRISTIQ treatment.
- On discontinuation, adverse events, some of which may be serious, have been reported with PRISTIQ and other SSRIs and SNRIs. Abrupt discontinuation of PRISTIQ has been associated with the appearance of new symptoms. Patients should be monitored for symptoms when discontinuing treatment. A gradual reduction in dose (by giving 50 mg of PRISTIQ less frequently) rather than abrupt cessation is recommended whenever possible.
- Dosage adjustment (50 mg every other day) is necessary in patients with severe renal impairment or end-stage renal disease (ESRD). The dose should not be escalated in patients with moderate or severe renal impairment or ESRD.
- Products containing desvenlafaxine and products containing venlafaxine should not be used concomitantly with PRISTIQ.
- Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ. Discontinuation of PRISTIQ should be considered in patients with symptomatic hyponatremia.
- Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of PRISTIQ) therapy have been rarely reported.

Adverse Reactions

- The most commonly observed adverse reactions in patients taking PRISTIQ vs placebo for MDD in short-term fixed-dose premarketing studies (incidence ≥5% and twice the rate of placebo in the 50-mg dose group) were nausea (22% vs 10%), dizziness (13% vs 5%), hyperhidrosis (10% vs 4%), constipation (9% vs 4%), and decreased appetite (5% vs 2%).

Reference: 1. Pristiq® (desvenlafaxine) Prescribing Information, Wyeth Pharmaceuticals Inc.

Please see brief summary of Prescribing Information on adjacent pages.

For more information on PRISTIQ, please visit **www.PristiqHCP.com**.

Pristiq® desvenlafaxine EXTENDED-RELEASE TABLETS

Wyeth®